Abstract: OBJECTIVES: Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver, and a CAR polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, we investigated their association with early (<3 months) discontinuation of efavirenz therapy. METHODS: Three hundred and seventy-three patients initiating therapy with an efavirenz-based regimen were included (278 white patients and 95 black patients; 293 male). DNA was extracted from whole blood and genotyping for CYP2B6 (516G → T, rs3745274), CAR (540C → T, rs2307424) and PXR (44477T → C, rs1523130; 63396C → T, rs2472677; and 69789A → G, rs763645) was conducted. Binary logistic regression using the backwards method was employed to assess the influence of SNPs and demographics on early discontinuation. RESULTS: Of the 373 patients, 131 withdrew from therapy within the first 3 months. Black ethnicity [odds ratio (OR) = 0.27; P = 0.0001], CYP2B6 516TT (OR = 2.81; P = 0.006), CAR rs2307424 CC (OR = 1.92; P = 0.007) and smoking status (OR = 0.45; P = 0.002) were associated with discontinuation within 3 months. CONCLUSIONS: These data indicate that genetic variability in CYP2B6 and CAR contributes to early treatment discontinuation for efavirenz-based antiretroviral regimens. Further studies are now required to define the clinical utility of these associations. were associated with discontinuation within three months.
Synopsis
Objectives: Cytochrome P450 2B6 (CYP2B6) is responsible for metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver and a CAR polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, we investigated their association with early (<3 months) discontinuation of efavirenz therapy.
Methods: 373 patients initiating therapy with an efavirenz based regimen were included (278 White and 95 Black; 293 male). DNA was extracted from whole blood and genotyping for CYP2B6 (516G>T, rs3745274), CAR (540C>T; rs2307424) and PXR (44477T>C, rs1523130; 63396C>T, rs2472677; 69789A>G, rs763645) were conducted.
Binary logistic regression by backwards method was used to assess the influence of SNPs and demographics on early discontinuation.
Introduction
Efavirenz treatment is associated with Central nervous system (CNS) or neuropsychiatric side effects in a large proportion of patients (~25%-70%) and can give symptoms such as dizziness, headache, abnormal dreams and sleep disturbance, mood changes, anxiety, dizziness and impaired concentration. [1] [2] [3] CNS side effects normally arise in the first days/weeks of treatment and for a small minority of patients can be prolonged for several months or emerge after numerous weeks of treatment 4 but do not always result in discontinuation of therapy. Discontinuation of efavirenzcontaining regimens has been reported with various frequencies in different studies, ranging from 5 to 20%, and neuropsychiatric side effects account for the majority of discontinuation cases. 3, [5] [6] [7] The causes of CNS and other side effects related to efavirenz containing regimens have not been fully characterised but some studies indicate that neuropsychiatric side effects are associated with high plasma concentrations, particularly in the first weeks of treatment. [8] [9] [10] Phase I metabolism of efavirenz is predominantly catalysed by cytochrome P450 2B6 (CYP2B6) and single nucleotide polymorphisms (SNPs) within the CYP2B6 gene are associated with altered hepatic CYP2B6 expression and activity. 11 The role of the 516G>T (rs3745274) SNP in pharmacokinetics of efavirenz has been studied extensively. [12] [13] [14] [15] [16] [17] [18] [19] In addition to CYP2B6, a secondary route of phase I metabolism of efavirenz is catalysed by CYP2A6 and CYP2A6 polymorphisms have also recently been identified as determinants of efavirenz plasma concentrations. [20] [21] [22] [23] The primary metabolite of phase I metabolism, 8-hydroxy efavirenz then undergoes glucuronidation prior to excretion in urine and bile. This phase II metabolism has recently been attributed to UDP-glucuronosyltransferase isoform 2B7 (UGT2B7) 24 and evidence is emerging that UGT2B7 polymorphisms are also associated with efavirenz plasma concentrations. 20 Hence, a thorough knowledge of the routes of metabolism and elimination of efavirenz have successfully identified candidate genes for pharmacogenetic studies.
The constitutive androstane receptor (CAR) and the preganane X receptor (PXR) are known to regulate a complex network of phase I and phase II metabolic enzymes in response to xenobiotics. Importantly, CAR and PXR expression also correlate with CYP2B6 25 and CYP2A6 26 expression in liver, even in the absence of enzyme inducers and xenobiotics. Activators of CAR have also been shown to induce UGT2B genes in vivo 27 and so CAR appears to play a role in basal and inducible regulation of the enzymes involved in efavirenz metabolism.
Therefore, we hypothesised that inter-individual variability in CAR and PXR caused, for example, by polymorphisms, would result in additional inter-individual variability in CYP2B6, CYP2A6 and UGT2B7. Single nucleotide polymorphisms have been reported in PXR 28 and CAR 29 genes and we have previously shown an association of a PXR SNP (63396C>T; rs2472677) with unboosted atazanavir plasma concentrations 30 and an association of a CAR SNP (540C>T; rs2307424) with plasma concentrations of efavirenz. 31 The aim of this study was to investigate the association of CYP2B6 (516G>T, rs3745274), CYP2A6 (CYP2A6*9B, rs8192726), UGT2B7 (735A>G, rs28365062; 802T>C, rs7439366), CAR (540C>T; rs2307424) and PXR (44477T>C, rs1523130; 63396C>T, rs2472677; 69789A>G, rs763645) polymorphisms with discontinuation within 3 months of initiating efavirenz-containing regimens. In addition, the association with demographic factors including ethnicity, smoking habits and gender were also investigated.
Patients and Methods

Patients
A total of 373 patients who were on stable efavirenz containing Highly Active Antiretroviral Therapy (HAART) for at least 3 months (n=242; control group) or who discontinued efavirenz containing HAART within 3 months (n = 131; early discontinuation group) were included in this cohort study. Out of 480 patients with stable efavirenz containing HAART identified as a potential control group, stored EDTA samples were available from 255 patients. In 13 of these patients genotyping for one or more SNP was not successful. Therefore 242 patients on stable therapy were included in the final analysis. The median duration of efavirenz therapy in this group was 48 months (range 5 -99 months). 213 patients were identified with early discontinuation of efavirenz-containing HAART, therefore fulfilling the inclusion criteria. In 131 patients EDTA samples were available and were therefore included in the analysis. The median duration or efavirenz exposure in this group was 1.1 month (range 0.2 -3 months).
Whole blood was provided by the KompNet Cohort. In this prospective multicenter, German-wide cohort semi-annual follow-up visits are documented and clinical and demographic data are collected. EDTA-samples are taken at enrolment and three years afterwards, serum samples are collected at every follow up visit. Demographic and clinical data were collected on: age, gender, weight, height, adherence (evaluated through pharmacy reports), ethnicity and qualitative smoking status. 32 Ethical approval was granted by the ethics committee of the Ruhr-Universität Bochum, Germany, and local ethics committee approval and informed consent was obtained at each site.
Genotyping
Total genomic DNA was isolated using the QIAamp DNA mini kit according to the manufacturer's instructions. Following extraction, purity was assessed by comparing the A 260 and A 280 ratio. DNA was quantified using PicoGreen® (PG) dsDNA Quantitation Reagent (Molecular Probes, CA, USA) and normalised to 20 ng/μL. For CYP2B6 preamplification was first conducted to discriminate from the CYP2B6 pseudogene (CYP2B7) by modification of previously reported methods. 
Statistical analysis
All data are given as frequency number (percentage) unless otherwise stated. The backbone therapy was comparable between the discontinuation group and the control group. Preferential NRTI-based backbone therapies consisting either of tenofovir/emtricitabine or lamivudine/zidovudine were used. The remaining patients were receiving alternative backbone or NRTI-free therapies. Within the early discontinuation group, 42 of 131 patients were taking lamivudine/zidovudine (or zidovudine) (32%) and 59 of 131 patients were taking tenofovir/emtricitabine (45%).
Within the control group 63 of 242 patients were taking lamivudine/zidovudine (26%) and 114 of 242 patients were receiving tenofovir/emtricitabine (47%). 
Association of demographics and backbone with early (<3 month) treatment discontinuation
Allele frequencies according to ethnicity
The frequency of the allelic variants in white and black patients are summarised in Table 2 
Association of genetic factors with early (<3 month) treatment discontinuation
When considering the entire population, CYP2B6 516G>T was statistically associated with early (<3 month) treatment discontinuation. 
Multivariate analysis by binary logistic regression
Multivariate logistic regression in the entire cohort confirmed the independent association of CYP2B6 516 and CAR rs2307424 genotypes with early (<3 month) treatment discontinuation. In addition to these genetic factors, ethnicity and smoking status were also identified as independent predictors. As shown in Table 3 
Composite analysis for genetic and demographic risk factors
To further confirm the association of these two polymorphisms with early discontinuation the CYP2B6 516T and CAR rs2307424 C alleles were classified as discontinuationassociated alleles. As shown in Figure 1A , the number of high discontinuationassociated alleles correlated with higher discontinuation. The rate of treatment discontinuation was: 25% (4 out of 16) for patients with no discontinuation-associated alleles, 29.6% (24 out of 81) for patients with one discontinuation-associated allele, 32.4% (48 out of 148) for patients with two alleles, 39.4% (43 out of 109) for patients with three alleles and 56.2% (9 out of 16) for patients with four alleles (p = 0.023; CAR genotype data were unavailable for 3 patients).
As shown in Figure 1B , the number of early discontinuation risk factors harboured by a patient (including CYP2B6 and CAR genetics, each allele counting as one risk factor; ethnicity; and smoking status) was associated with early discontinuation. Inter-individual variability in metabolism and disposition genes for efavirenz may influence onset of side effects and therefore therapy discontinuation. CYP2B6 516 has been identified as a major predictor of efavirenz plasma concentrations [12] [13] [14] [15] [16] [17] [18] [19] and a correlation between frequency of CNS side effects in white patients and slow-metaboliser genotypes (CYP2B6 516TT and 983TT) was recently described. 33 In the current cohort TT homozygosity for the CYP2B6 516 G>T polymorphism was independently associated with early treatment discontinuation.
A novel association between a CAR polymorphism (rs2307424) and plasma efavirenz concentrations was recently reported by some of the investigators involved in the present study. 31 The discontinuation data presented here extends these findings to a clinical phenotype, showing significant association of CC genotype with early treatment discontinuation. These findings strengthen the role of CAR in efavirenz disposition and pharmacokinetics, presumably through its role in the regulation of CYP2B6.
A genetic composite of these two polymorphisms (CYP2B6 516 C>T and CAR rs2307424) was assessed and patients with more discontinuation-associated alleles (also the same as the high concentration-associated alleles 31 ) had a higher rate of discontinuation. This finding reinforces the hypothesis that early treatment discontinuation is associated with higher plasma concentrations. However, it must be noted that plasma efavirenz concentrations are higher in black patients than in white patients 34 , yet treatment discontinuation rates appear to be lower in black patients. 35 In the present study, white patients had a higher frequency of early discontinuation than black patients. Furthermore, the frequency of CYP2B6 and CAR alleles associated with higher plasma efavirenz concentrations are more frequent in black patients. We hypothesise that this apparent paradox may be explained by inter-ethnic variability in other unknown genes involved in the aetiology of CNS toxicity.
Smoking status was also identified as being independently associated with early treatment discontinuation. We previously reported a trend towards an association between smoking and efavirenz plasma concentrations in the German Competence
Network for HIV/AIDS 19 and in a Chilean cohort. 31 Interestingly, nicotine has previously been shown to activate nuclear receptors such as PXR and CAR 36 and induction of CYP2B6 has been described. 37 Furthermore, nicotine and efavirenz have an overlapping elimination pathway, both metabolised by CYP2B6 and CYP2A6, providing another putative mechanisms for the interaction. 38 Nicotine exposure has also been shown to influence blood-brain barrier permeability in-vivo 39, 40 and may therefore have an effect on efavirenz diffusion in CNS, independently of effects on pharmacokinetics.
It must be noted that a major limitation of the current study is that the reasons for early discontinuation were not known for 42% of the cohort. However, of those discontinuing therapy for known reason, 94.7% discontinued due to CNS toxicity. Other reasons for an early treatment discontinuation (e.g. virological failure) usually lead to later (> 3 months) discontinuation or modification of therapy. For this reason it seems likely that in the majority of patients the reason for the treatment discontinuation was CNS toxicity.
Moreover, the reported associations were also present when univariate logistic analysis was conducted for patients that discontinued due to known CNS toxicity (n = 72), CAR rs2307424CC (OR = 1.86, p = 0.037), CYP2B6 516TT (OR = 2.1, p = 0.122) and black ethnicity (OR = 0.42, p = 0.013). A potential additional limitation of this study is that no information was collected with respect to their adherence to medication.
In conclusion, our findings indicate that genetic variability in genes involved in the metabolism and disposition of efavirenz are determinants of early (<3 month) treatment discontinuation. These data provide evidence that smoking status may be associated with discontinuation. In-vitro studies to identify the mechanisms underpinning these associations and to identify toxicological targets in the brain are now warranted.
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Barchart to represent % of patients discontinuing treatment within 3 months and number of discontinuation-associated alleles (CYP2B6 516T and CAR rs2307424C, A) and number of discontinuation-associated risk factors (CYP2B6 516T and CAR rs2307424C, white ethnicity, and smoking; B).
